This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Array Seeks Asthma Drug Partner Following Mid-Stage Study Results

BOULDER, Col. ( TheStreet) -- An experimental pill from Array BioPharma (ARRY - Get Report) improved lung function in patients who suffer from asthma brought on by allergies, according to results from a small mid-stage study announced Tuesday.

Array shares rose 15 percent to $6.40 in early trading on the data from the study of ARRY-502 in allergic asthma. The company is seeking a partner to fund the future development of the drug.

Asthma affects approximately 25 million, or 8 percent, of the U.S. population but no new oral medication for the disease has been approved since Merck's (MRK - Get Report) Singulair in 1998. Singulair was a $5 billion-plus drug for Merck before its patent expired and generic copies became available.

Array's ARRY-502 is designed to block the inflammatory activity of Th2 T cells, which in turn, reduces the coughing and breathing difficulties seen in asthma patients. This represents a potentially new way of treating asthma, Array said. Drugs with similar mechanisms of action developed by Amgen (AMGN - Get Report) and Actelion were not successful.

In the study, 184 patients with mild, moderate and persistent allergic asthma were randomized to treatment with ARRY-502 taken twice per day or a placebo. After four weeks of treatment, lung function in patients treated with ARRY-502 improved by 3.9 percent relative to placebo. The benefit was statistically significant.

Lung function was assessed by FEV1, which measures the amount of air that can be exhaled by a patient in one second.

Array did not disclose the absolute improvement or decline in FEV1 function for the patients treated with ARRY-502 or placebo.

Approximately half of the asthma patients enrolled in the study had an undisclosed biomarker associated with Th2 activity, suggesting they might benefit more from a drug like ARRY-502. In these patients, treatment with Array's drug led to a 6.8 percent relative improvement in lung function compared to placebo.

Array says its research indicates that about 25 percent of all asthma patients possess this biomarker for enhanced Th2 activity.

On the safety side, there were not serious adverse events in patients treated with ARRY-502, while all treatment-related adverse events were mild or moderate, the company said, without providing details. Elevent patients in the placebo group and four patients in the ARRY-502 arm discontinued the study early.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
ARRY $7.19 0.00%
AMGN $167.91 0.00%
MRK $57.60 0.00%
AAPL $130.28 0.00%
FB $81.53 0.00%

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs